BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,818,000 | -34.8% | 8,817 | -22.1% | 0.08% | -22.4% |
| Q4 2021 | $5,855,000 | -5.3% | 11,317 | -11.3% | 0.10% | -11.7% |
| Q3 2021 | $6,182,000 | -19.5% | 12,757 | -25.2% | 0.11% | -17.8% |
| Q2 2021 | $7,680,000 | +11.3% | 17,057 | -5.6% | 0.14% | +17.4% |
| Q1 2021 | $6,900,000 | +20.6% | 18,067 | +0.3% | 0.12% | +9.5% |
| Q4 2020 | $5,723,000 | +28.2% | 18,021 | 0.0% | 0.10% | +7.1% |
| Q3 2020 | $4,464,000 | -6.8% | 18,021 | -0.6% | 0.10% | -11.7% |
| Q2 2020 | $4,788,000 | +39.3% | 18,131 | 0.0% | 0.11% | +19.4% |
| Q1 2020 | $3,438,000 | -11.3% | 18,131 | +2.7% | 0.09% | +14.8% |
| Q4 2019 | $3,874,000 | +2.3% | 17,650 | -8.8% | 0.08% | +9.5% |
| Q3 2019 | $3,788,000 | +40.8% | 19,360 | +50.1% | 0.07% | +32.1% |
| Q2 2019 | $2,690,000 | +287.1% | 12,900 | +268.6% | 0.06% | +273.3% |
| Q1 2019 | $695,000 | -34.3% | 3,500 | -43.5% | 0.02% | +25.0% |
| Q4 2018 | $1,058,000 | +92.0% | 6,200 | +129.6% | 0.01% | 0.0% |
| Q3 2018 | $551,000 | – | 2,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |